In pancreatic cancer models, the reprogramming of TAMs through colony-stimulating factor 1 (CSF1)/colony-stimulating factor 1 receptor (CSF-1R) blockade enhances the response to T-cell checkpoint immunotherapy [159]. The gene discussed is CSF1; the disease is familial pancreatic carcinoma.